The Effect of Priacetam in Aphasia due to Acute Brain Ischemic Stroke: Clinical trial

Authors

  • A Hamzei-Moghaddam Professor of Neurology, Afzalipour School of Medicine & Neurology Research Center, Kerman University of Medical Sciences, Kerman, Iran
  • M Akbari Master of Speechtherapy, Students’ Research Committee, Kerman University ofMedical Sciences, Kerman, Iran
  • M Nazari Resident of Neurology, Afzalipour School of Medicine, Kerman University ofMedical Sciences, Kerman, Iran
  • M.A Shafa Assistant Professor of Neurology, Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman, Iran
Abstract:

Background & Aims: Stroke incidence is 15 million people world wide annually and one third of these patients suffer from aphasia. Aphasia is often associated with significant disability in patients. Costs due to cerebrovascular diseases play an important role in national health expenditures. We aimed to assess the effect of piracetam in treatment of aphasia. Methods: Patients with acute ischemic stroke after completing informed consent form were divided randomly into two groups. The intervention group recieved standard treatment and 4800 mg piracetam daily for 12 weeks and the control group received standard treatment plus placebo. All patients on admission, and one, two, and three months post-stroke were evaluated using Nilipour Farsi aphasia test. Results: A total of 40 patients with stroke and mean age of 60.1 ± 17.2 years were assessed. Among them, the Broca aphasia had the most frequency and global and Wernicke aphasia had the least. The aphasia test showed significant difference between the intervention and control groups at the first and second months of follow-up; but the difference was not significant at the third month. Conclusion: Totally, piracetam does not affect the rate of recovery from aphasia, despite increasing patients' early recovery

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

The Effect of Intravenous Magnesium Sulfate in Improvement of Acute Ischemic Stroke Induced Disability: A Randomized Double Blinded Clinical Trial

Background: Stroke is the third main cause of death and chronic disabilities in adults, which requires finding neuroprotective drugs to reduce its mortality and morbidity.  Objectives: To determine the efficacy of magnesium sulfate as an adjunctive neuroprotective agent in patients with stroke. Materials & Methods: This randomized double-blind clinical trial recruited 120 patients with acute ...

full text

Effect of Lithium on Brain-derived Neurotrophic Factor (BDNF) Level in Patients with Ischemic Stroke: A Clinical Trial

Background and Objectives: Previous studies have indicated that lithium may increase the level of the brain-derived neurotrophic factor (BDNF), which in turn improves the recovery of patients with stroke. In this controlled trial we evaluated the effect of lithium on BDNF serum level in patients with ischemic stroke. Methods: In this randomized controlled...

full text

dysphagia in acute ischemic stroke

Introduction: Swallowing dysfunction complicates acute strokes in 25-32% of cases and directly affects patientschr('39') prognosis and recovery. Dysphagia complicates the course of acute strokes through its potential of the development of chest infection, nutritional problems, and dehydration.  Dysphagia is also an independent predictor of respiratory morbidity and mortality in acute stroke. In...

full text

The Effect of Repetitive Transcranial Magnetic Stimulation on Postural Stability After Acute Stroke: A Clinical Trial

Introduction: Balance impairment is a common problem and a major cause of motor disability after stroke. Therefore, this study aimed to investigate whether low-frequency repetitive Transcranial Magnetic Stimulation (rTMS) improves the postural balance problems in stroke patients. Methods: This randomized double blind clinical trial with 12 weeks follow-up was conducted on stroke patients. Trea...

full text

Intravenous Thrombolysis for Acute Ischemic Stroke due to Cardiac Myxoma; A Case Report

Myxoma may cause systemic embolization and frequently presents as ischemic stroke. There has been debates whether it is safe to use recombinant tissue plasminogen activator (rt-PA) in patients with cardiac myxoma who are presented with ischemic stroke at emergency department. we describe a young case of atrial myxoma with initial presentation of acute cerebral infarction symptoms who was treate...

full text

O10: Thrombo-Inflammation in Acute Ischemic Stroke

Ischemic stroke has been classified as a merely thrombotic disease, so the main goal of its treatment is the recanalization of the occluded vasculature. However, despite fast restoration of blood circulation, progressive stroke still develops in many patients, which has led to the concept of reperfusion injury.  The underlying mechanism is only partly known. Though, it is accepted now, tha...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 21  issue 3

pages  219- 229

publication date 2014-06-01

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023